Literature DB >> 7496336

Intercellular adhesion molecule-1 levels in plasma and vitreous from patients with vitreoretinal disorders.

P Esser1, M Bresgen, R Fischbach, K Heimann, P Wiedemann.   

Abstract

Intercellular adhesion molecule 1 (ICAM-1) is a member of the immunoglobulin superfamily with important functions in immune activation and inflammation. Its interaction with different cytokines [interleukin 1 (IL-1), tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma)] is important for lymphocyte migration into inflammatory sites. We used a sandwich enzyme immunoassay (EIA) for the quantitative determination of soluble ICAM-1 (cICAM-1) in vitreous and plasma from patients undergoing vitrectomy for a variety of proliferative vitreoretinal disorders. The values obtained were compared with the total vitreal protein. The respective concentrations of cICAM-1 in vitreous were as follows control samples, 3.47 +/- 1.84 ng/ml; proliferative diabetic retinopathy (PDR) of diabetes type I 27.43 +/- 14.72 ng/ml; PDR of diabetes type II, 32.46 +/- 10.31 ng/ml; idiopathic proliferative vitreoretinopathy 35.74 +/- 15.30 ng/ml; and traumatic PVR, 45.23 +/- 24.24 ng/ml. Plasma samples yielded the following concentrations: controls, 415 +/- 43.4 ng/ml; PDR of diabetes type I, 469 +/- 96.9 ng/ml; PDR of diabetes type II, 425 +/- 65.4 ng/ml; idiopathic PVR, 402 +/- 119.9 ng/ml; and traumatic PVR, 434 +/- 118.6 ng/ml. Our results demonstrate high levels of ICAM-1 in most proliferative vitreoretinal disorders. In PDR and in traumatic PVR, cICAM-1 levels were elevated significantly more than were total vitreal protein levels. In traumatic PVR, patients with a short interval between previous surgery or traumatic event demonstrated the highest levels of cICAM. Since plasma levels were not significantly altered, we suggest that local cICAM-1 production, possibly from macrophages, may be of importance in the early phase of PVR and PDR by enhancing immune activation and inflammation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7496336

Source DB:  PubMed          Journal:  Ger J Ophthalmol        ISSN: 0941-2921


  12 in total

Review 1.  Involvement of Müller glial cells in epiretinal membrane formation.

Authors:  Andreas Bringmann; Peter Wiedemann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-05-05       Impact factor: 3.117

2.  Neuroprotection from retinal ischemia/reperfusion injury by NOX2 NADPH oxidase deletion.

Authors:  Harumasa Yokota; Subhadra P Narayanan; Wenbo Zhang; Hua Liu; Modesto Rojas; Zhimin Xu; Tahira Lemtalsi; Taiji Nagaoka; Akitoshi Yoshida; Steven E Brooks; Robert W Caldwell; Ruth B Caldwell
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-10-11       Impact factor: 4.799

3.  Vitreous levels of intercellular adhesion molecule 1 (ICAM-1) as a risk indicator of proliferative vitreoretinopathy.

Authors:  G A Limb; A H Chignell
Journal:  Br J Ophthalmol       Date:  1999-08       Impact factor: 4.638

4.  Immunohistochemical study of vascular endothelial growth factor (VEGF), tumor suppressor protein (p53) and intercellular adhesion molecule (ICAM-1) in the conjunctiva of diabetic patients.

Authors:  Lidia Kria; Taoufik Khalfaoui; Ghada Mkannez; Omar Beltaief; Raja Anane; Khalil Errais; Lilia Tounsi; Raja Zhioua; Sarra Ben Jilani; Amel Meddeb Ouertani
Journal:  J Mol Histol       Date:  2006-02-16       Impact factor: 2.611

5.  Neuroprotective effect of water-dispersible hesperetin in retinal ischemia reperfusion injury.

Authors:  Akito Shimouchi; Harumasa Yokota; Shinji Ono; Chiemi Matsumoto; Toshihiro Tamai; Hiroko Takumi; Subbadra P Narayanan; Shoji Kimura; Hiroya Kobayashi; Ruth B Caldwell; Taiji Nagaoka; Akitoshi Yoshida
Journal:  Jpn J Ophthalmol       Date:  2015-09-25       Impact factor: 2.447

Review 6.  Vascular endothelial growth factor in eye disease.

Authors:  J S Penn; A Madan; R B Caldwell; M Bartoli; R W Caldwell; M E Hartnett
Journal:  Prog Retin Eye Res       Date:  2008-05-28       Impact factor: 21.198

Review 7.  The Vitreous Ecosystem in Diabetic Retinopathy: Insight into the Patho-Mechanisms of Disease.

Authors:  Siva S R Iyer; Mollie K Lagrew; Stephanie M Tillit; Ramak Roohipourmoallai; Samuel Korntner
Journal:  Int J Mol Sci       Date:  2021-07-01       Impact factor: 5.923

Review 8.  Therapeutic interventions against inflammatory and angiogenic mediators in proliferative diabetic retinopathy.

Authors:  Daniel Gologorsky; Aristomenis Thanos; Demetrios Vavvas
Journal:  Mediators Inflamm       Date:  2012-09-17       Impact factor: 4.711

9.  Interleukin and growth factor levels in subretinal fluid in rhegmatogenous retinal detachment: a case-control study.

Authors:  Lukas J A G Ricker; Aize Kijlstra; Alfons G H Kessels; Wilco de Jager; Albert T A Liem; Fred Hendrikse; Ellen C La Heij
Journal:  PLoS One       Date:  2011-04-27       Impact factor: 3.240

10.  Therapeutic effects of PPARα agonists on diabetic retinopathy in type 1 diabetes models.

Authors:  Ying Chen; Yang Hu; Mingkai Lin; Alicia J Jenkins; Anthony C Keech; Robert Mott; Timothy J Lyons; Jian-xing Ma
Journal:  Diabetes       Date:  2012-10-05       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.